A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer
Kamata, T.; Hayashi, Y.; Minatoya, G.; Michiwa, Y.; Onishi, I.; Takeda, T.; Koyasaki, N.; Kanno, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(10): 1419-1422
2001
ISSN/ISBN: 0385-0684 PMID: 11681250 Document Number: 526250
TS-1, a novel oral formation of 5-fluorouracil, consists of tegafur (5-FU), CDHP and Oxo. Low-dose cisplatin (CDDP) and TS-1 was evaluated in 12 patients with advanced or recurrent gastric cancer. CDDP was given biweekly at a dose of 15 mg/m2 infused for 30 minutes, and 80 mg/body of TS-1 was orally administered as many times as possible. The response rate was 41.7%. Median survival time was 13.3 months. In one case, an adverse reaction of grade 3 leucopenia was observed. Thus, thought it is necessary to watch for leucopenia, this chemotherapy could well be effective for patients with advanced or recurrent gastric cancer.